Work

Review Article Brexanolone: A Pharmacotherapy Approach in Post Partum Depression

Year: 2021

Type: article

Abstract: Postpartum depression is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered as a life-threatening condition in postpartum women’s. Brexanolone is an efficient drug approved for the first time by the USFDA on March 19, 2019 for immediate release through Intravenous route used for the treatment of postpartum depression (PPD). This review article is about the detailed information of Brexanolone includes its drug information, mechanism of action, pharmacokinetic and pharmacodynamics studies, side effects, drug prescribing detail. This article also includes the information about the postpartum depression- its epidemiology, etio-pathology, signs and symptoms, diagnostic pattern.

Source: Advances in Pharmacoepidemiology & Drug Safety

Authors: N Priyanka, S Shalini

Language: English

Topic: Maternal Mental Health During Pregnancy and Postpartum

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W3175280057

FWCI:

Cites: 12

Cited by:

Related to: 10